The Impact of Primary Tumor Volume on Survival of Patients with Non-Surgically Treated Advanced-Stage Hypopharyngeal Cancer- Retrospective Study and Literature Overview

被引:0
|
作者
Jakovljevic, Sasa [1 ,2 ]
Djordjevic, Vladimir [1 ,2 ]
Tomanovic, Nada [1 ,3 ]
Arsovic, Nenad [1 ,2 ]
Dudvarski, Zoran [1 ,2 ]
Ursulovic, Tamara [4 ]
Laketic, Darko [1 ,5 ]
Jovanovic, Katarina [2 ]
Arsovic, Konstantin [2 ]
Radivojevic, Nemanja [1 ,2 ]
机构
[1] Univ Belgrade, Fac Med, Belgrade 11000, Serbia
[2] Univ Clin Ctr Serbia, Clin Otorhinolaryngol & Maxillofacial Surg, Belgrade, Serbia
[3] Inst Pathol, Belgrade, Serbia
[4] Inst Oncol & Radiol Serbia, Belgrade, Serbia
[5] Inst Anat, Belgrade, Serbia
关键词
Advanced hypopharyngeal cancer; Cancer prognosis; Non-surgical treatment; Tumor volume; Survival; SQUAMOUS-CELL CARCINOMA; ADVANCED HEAD; NECK-CANCER; LARYNX CANCER; PROGNOSTIC-FACTORS; LOCAL-CONTROL; RADIOCHEMOTHERAPY; CHEMORADIATION; PRESERVATION; RADIOTHERAPY;
D O I
10.1007/s12070-024-05139-z
中图分类号
R61 [外科手术学];
学科分类号
摘要
To determine the prognostic value of tumor volume in predicting the survival in patients with stage III-IV of hypopharyngeal carcinoma. We studied 71 patients with advanced stage of hypopharyngeal carcinoma. The volume of primary tumor was calculated by approximation of the ellipsoid volume. Correlation between carcinoma volume and demographic, clinical and carcinoma characteristics has shown that male patients and patients consuming alcohol had greater tumor volumes. The median of overall survival was at 12 months (95% CI: 9.25-14.75); the median of progression-free survival was at 9 months (95% CI: 6.6-11.3). ROC Curve Analysis of carcinoma volumes in outcome prediction shows that the cutoff of 14.69 had the sensitivity of 61% and specifics of 89%. Based on significant independent impact of tumor volume on survival, it is important to include this parameter among possible new treatment protocols.
引用
收藏
页码:184 / 193
页数:10
相关论文
共 50 条
  • [31] Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy
    Stinchcombe, TE
    Morris, DE
    Moore, DT
    Bechtel, JH
    Halle, JS
    Mears, A
    Deschesne, K
    Rosenman, JG
    Socinski, MA
    LUNG CANCER, 2006, 52 (01) : 67 - 74
  • [32] Prognostic factors predicting survival in incurable stage IV colorectal cancer patients who underwent palliative primary tumor resection. Retrospective cohort study
    Kim, Min Sung
    Park, Eun Jung
    Kang, Jeonghyun
    Min, Byung Soh
    Lee, Kang Young
    Kim, Nam Kyu
    Baik, Seung Hyuk
    INTERNATIONAL JOURNAL OF SURGERY, 2018, 49 : 10 - 15
  • [33] Association of Primary Tumor Volume With Survival in Patients With T3 Glottic Cancer Treated With Radiotherapy A Study of the Canadian Head & Neck Collaborative Research Initiative
    Malik, Nauman H.
    Fu, Rui
    Hainc, Nicolin
    Noel, Christopher W.
    de Almeida, John R.
    Hosni, Ali
    Huang, Shao Hui
    Yu, Eugene
    Dzioba, Agnieszka
    Leung, Andrew
    Mangat, Arvindpaul
    MacNeil, Danielle
    Nichols, Anthony C.
    Hiremath, Shivaprakash B.
    Chakraborty, Santanu
    Jooya, Alboorz
    Gaudet, Marc
    Johnson-Obaseki, Stephanie
    Whelan, Jonathan
    Forghani, Reza
    Hier, Michael P.
    Morand, Gregoire
    Sultanem, Khalil
    Dort, Joseph
    Lysack, John
    Matthews, Wayne
    Nakoneshny, Steven
    Gill, Gia
    Globerman, Adam
    Kerr, Paul
    Maralani, Pejman
    Karam, Irene
    Eskander, Antoine
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2023, 149 (02) : 103 - 109
  • [34] Prognostic impact of c-MET status on overall survival of patients with advanced gastric cancer treated with standard chemotherapy: A Japanese multicenter collaborative retrospective study
    Kuboki, Y.
    Fuse, N.
    Kuwata, T.
    Shinozaki, E.
    Machida, N.
    Yuki, S.
    Kajiura, S.
    Yamanaka, T.
    Ochiai, A.
    Ohtsu, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S635 - S635
  • [35] Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: A retrospective study
    Miura, Kaho
    Sano, Yoshiyuki
    Niho, Seiji
    Kawasumi, Kenji
    Mochizuki, Nobuo
    Yoh, Kiyotaka
    Matsumoto, Shingo
    Zenke, Yoshitaka
    Ikeda, Takaya
    Nosaki, Kaname
    Kirita, Keisuke
    Udagawa, Hibiki
    Goto, Koichi
    Kawasaki, Toshikatsu
    Hanada, Kazuhiko
    THORACIC CANCER, 2021, 12 (13) : 1983 - 1994
  • [36] Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235
    Bazan, Jose G.
    Duan, Fenghai
    Snyder, Bradley S.
    Horng, Dunstan
    Graves, Edward E.
    Siegel, Barry A.
    Machtay, Mitchell
    Loo, Billy W., Jr.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 17 - 24
  • [37] Metabolic tumor volume predicts overall survival and local control in patients with stage III non-small cell lung cancer treated in ACRIN 6668/RTOG 0235
    Jose G. Bazan
    Fenghai Duan
    Bradley S. Snyder
    Dunstan Horng
    Edward E. Graves
    Barry A. Siegel
    Mitchell Machtay
    Billy W. Loo
    European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 : 17 - 24
  • [38] Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan
    Lin, Shu-Yung
    Yang, Ching-Yao
    Liao, Bin-Chi
    Ho, Chao-Chi
    Liao, Wei-Yu
    Chen, Kuan-Yu
    Tsai, Tzu-Hsiu
    Hsu, Chia-Lin
    Hsu, Wei-Hsun
    Su, Kang-Yi
    Chang, Yih-Leong
    Lee, Jih-Hsiang
    Lin, Chia-Chi
    Shih, Jin-Yuan
    Yang, James Chih-Hsin
    Yu, Chong-Jen
    JOURNAL OF CANCER, 2018, 9 (10): : 1813 - 1820
  • [39] Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib
    Hida, Tomoyuki
    Dahlberg, Suzanne E.
    Lydon, Christine A.
    Hatabu, Hiroto
    Johnson, Bruce E.
    Awad, Mark M.
    Nishino, Mizuki
    JOURNAL OF THORACIC IMAGING, 2020, 35 (02) : 101 - 107
  • [40] Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Patients Treated with EGFR TKI
    Nishino, Mizuki
    Dahlberg, Suzanne E.
    Cardarella, Stephanie
    Jackman, David M.
    Rabin, Michael S.
    Hatabu, Hiroto
    Jaenne, Pasi A.
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (08) : 1059 - 1068